Skip to content
Screener

Castle Biosciences CSTL Investing Cash Flow

Investing Cash Flow at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
-$366.2M-289%
Veracyte logo
VeracyteVCYT
-$127.96M-147%
Lucid Diagnostics logo
Lucid DiagnosticsLUCD
-$215K-131%
Myriad Genetics logo
Myriad GeneticsMYGN
-$6.5M+21.7%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$46.01M-104%
NeoGenomics logo
NeoGenomicsNEO
-$8.32M+10.7%

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$978.5M+76.1%
Enterprise value$951.46M+86.2%
P/S2.9×+1.3×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-031263
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from sale of equity securities2,681
Purchases of property and equipment(12,455)(4,740)
Proceeds from sale of property and equipment79
Net cash used in investing activities(25,803)(22,431)
FINANCING ACTIVITIES
Proceeds from exercise of common stock options32218
Payment of employees’ taxes on vested restricted stock units and performance-based restricted stock units(6,598)(2,515)
Proceeds from contributions to the employee stock purchase plan1,267970

Item 1. Financial Statements.

FAQ

What is Castle Biosciences's investing cash flow?
Castle Biosciences (CSTL) reported investing cash flow of -$25.8M in Q1 2026.
How has Castle Biosciences's investing cash flow changed year-over-year?
Castle Biosciences's investing cash flow decreased by 15.0% year-over-year, from -$22.43M to -$25.8M.
What is the long-term trend for Castle Biosciences's investing cash flow?
Over 2 years (2021 to 2023), Castle Biosciences's investing cash flow has grown at a -50.7% compound annual growth rate (CAGR), from -$66.66M to -$16.18M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Castle Biosciences's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude